Inventor · disambiguated record
Minzhen Xu
Also filed as: XU MINZHEN
14 granted patents·8 pending applications·178 citations·filing 1996–2018
92Inventor score
Top patents by PatentIndex Score
22 records- 0191US7179645B2Ii-Key/antigenic epitope hybrid peptide vaccinesANTIGEN EXPRESS INC·Filed 2002·Granted Feb 20, 2007·54 cites·8 claims
- 0289US8815249B2Ii-key/antigenic epitope hybrid peptide vaccinesHUMPHREYS ROBERT·Filed 2010·Granted Aug 26, 2014·8 cites·8 claims
- 0387US7935350B2Ii-key/Her-2/neu hybrid cancer vaccineANTIGEN EXPRESS INC·Filed 2007·Granted May 3, 2011·4 cites·4 claims
- 0483US5919639AIi peptide therapeutics to enhance antigen presentationUNIV MASSACHUSETTS·Filed 1997·Granted Jul 6, 1999·40 cites·8 claims
- 0582US7541334B2Hybrid peptides modulate the immune responseANTIGEN EXPRESS INC·Filed 2007·Granted Jun 2, 2009·3 cites·1 claims
- 0677US7205274B2Hybrid peptides modulate the immune responseANTIGEN EXPRESS INC·Filed 2002·Granted Apr 17, 2007·6 cites·3 claims
- 0773US9289487B2II-key/antigenic epitope hybrid peptide vaccinesHUMPHREYS ROBERT·Filed 2005·Granted Mar 22, 2016·4 cites·8 claims
- 0873US8889143B2Ii-key/HER-2/neu hybrid cancer vaccineHUMPHREYS ROBERT·Filed 2009·Granted Nov 18, 2014·0 cites·3 claims
- 0971US6432409B1Hybrid peptides modulate the immune responseANTIGEN EXPRESS INC·Filed 1999·Granted Aug 13, 2002·24 cites·6 claims
- 1070US2010255019A1Ii-KEY/HER-2/NEU HYBRID CANCER VACCINEHUMPHREYS ROBERT·Filed 2009·Application pending·0 cites
- 1166US8748130B2Human papillomavirus / Ii-Key hybrids and methods of useXU MINZHEN·Filed 2009·Granted Jun 10, 2014·1 cites·4 claims
- 1264US2015093402A1Ii-KEY/HER-2/NEU HYBRID CANCER VACCINEANTIGEN EXPRESS INC·Filed 2014·Application pending·0 cites
- 1362US5726020AInhibition of II synthesisUNIV MASSACHUSETTS·Filed 1996·Granted Mar 10, 1998·23 cites·23 claims
- 1456US11389475B2Method for inducing an M1 dominated immune response and pharmaceutical compositionsXU MINZHEN·Filed 2018·Granted Jul 19, 2022·0 cites·4 claims
- 1556US6368855B1MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expressionANTIGEN EXPRESS INC·Filed 1998·Granted Apr 9, 2002·11 cites·39 claims
- 1655US2008305122A1Ii-Key/antigenic epitope hybrid peptide vaccinesANTIGEN EXPRESS INC·Filed 2007·Application pending·0 cites
- 1749US2003235594A1Ii-Key/antigenic epitope hybrid peptide vaccinesANTIGEN EXPRESS INC·Filed 2002·Application pending·0 cites
- 1848US2006008448A1Inhibition of li expression in mammalian cellsXU MINZHEN·Filed 2004·Application pending·0 cites
- 1948US2003198626A1Inhibition of Ii expression in mammalian cellsANTIGEN EXPRESS INC·Filed 2002·Application pending·0 cites
- 2046US2003054365A1MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expressionANTIGEN EXPRESS INC·Filed 2002·Application pending·0 cites
- 2145US2009060889A1Ii-RNAi involved Ii suppression in cancer immunotherapyVON HOFE ERIC·Filed 2008·Application pending·0 cites
- 2233US6835382B2Ii peptide therapeutics to enhance antigen presentationUNIV MASSACHUSETTS·Filed 1999·Granted Dec 28, 2004·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when Minzhen Xu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →